Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 8th, 2007 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), is entered into as of July 8, 2007 (the “Execution Date”), by and among F. Hoffmann-La Roche Ltd, a Swiss corporation (“Roche Basel”), having a place of business at Grenzacherstrasse 124, CH-4070 Basel, Switzerland, and Hoffmann-La Roche Inc., a New Jersey corporation (“Roche Nutley”), having a place of business at 340 Kingsland Street, Nutley, New Jersey 07110, U.S.A. (Roche Basel and Roche Nutley, collectively, “Licensee”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142, U.S.A. (“Alnylam”), and, solely for the purposes set forth in Section 9.15 of this Agreement, Alnylam Europe AG, a German stock corporation, with a registered office in Kulmbach, Germany (“Alnylam Europe AG”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. TERMINATION AGREEMENTTermination Agreement • November 8th, 2007 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS TERMINATION AGREEMENT, dated September 18, 2007 (this “Agreement”), is made by and between MERCK & Co., Inc., a corporation organized and existing under the laws of New Jersey (“MERCK”) and ALNYLAM Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (“ALNYLAM”; MERCK and ALNYLAM together are referred to herein as the “Parties”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. Limited Liability Company Agreement of Regulus Therapeutics LLC a Delaware Limited Liability Company Dated as of September 6, 2007Limited Liability Company Agreement • November 8th, 2007 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”) of Regulus Therapeutics LLC, a Delaware limited liability company (the “Company”), is entered into as of September 6, 2007 (the “Effective Date”) by and among the Company, Alnylam Pharmaceuticals, Inc., a Delaware corporation (“Alnylam”), and Isis Pharmaceuticals, Inc., a Delaware corporation (“Isis,” and together with Alnylam, the “Members”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. AMENDED AND RESTATED COLLABORATION AGREEMENT BY AND BETWEEN ALNYLAM PHARMACEUTICALS, INC. AND MEDTRONIC, INC.Collaboration Agreement • November 8th, 2007 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Collaboration Agreement (this “Agreement”) is entered into as of the 27th day of July, 2007 (the “Restatement Date”), by and between Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”), and Medtronic, Inc., a corporation organized and existing under the laws of the State of Minnesota and having its principal office at 710 Medtronic Parkway, Minneapolis, Minnesota 55432 (“Medtronic”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • November 8th, 2007 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This License and Collaboration Agreement (the “License Agreement” or the “Agreement”) is entered into as of the 6th day of September 2007 (the “Effective Date”) by and among Alnylam Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142 (“Alnylam”), Isis Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 1896 Rutherford Road, Carlsbad, California 92008 (“Isis”, and each of Alnylam and Isis, a “Licensor” and together, the “Licensors”), and Regulus Therapeutics LLC, a Delaware limited liability company, with its principal place of business at 1896 Rutherford Road, Carlsbad, California 92008 (“Regulus”).
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • November 8th, 2007 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) dated as of July 8, 2007, between ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and ROCHE FINANCE LTD, a Swiss corporation (the “Purchaser”).
